Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Combination Therapy for High-Risk Multiple Myeloma
NCT05497804Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2022
- Primary completion
- Feb 2026
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, daratumumab, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Mayo Clinic. Started Sep 2022; status: active, not recruiting.
02
Drugs
carfilzomibdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05497804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497804.